Analysis of the Impact of Helicobacter Pylori on Salivary Microbiome in Adults
NCT ID: NCT03730766
Last Updated: 2018-11-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
60 participants
INTERVENTIONAL
2018-08-01
2018-11-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment
NCT05250050
Helicobacter Pylori Eradication and Follow-up
NCT05061732
PPI-amoxicillin for H. Pylori Treatment
NCT05014685
Bismuth-Metronidazole Triple Therapy for H. Pylori First-line Treatment
NCT04667299
Efficacy and Safety of Dual Therapy as First-line Treatment for Hp Infection
NCT05419674
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bismuth Plus triple Therapy
Esomeprazole 20mg bid, Bismuth Potassium Citrate 600mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
Esomeprazole
Proton pump inhibitor
Amoxicillin
Antibiotics for H. pylori eradication
Bismuth Potassium Citrate
Gastric mucosal protective drug with anti-H. pylori effect
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Esomeprazole
Proton pump inhibitor
Amoxicillin
Antibiotics for H. pylori eradication
Bismuth Potassium Citrate
Gastric mucosal protective drug with anti-H. pylori effect
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability and willingness to participate in the study and to sign and give informed consent
* Received both endoscopy and 13C urea breath test (13C-UBT) before enrolled
Exclusion Criteria
* With previous gastric surgery
* Major systemic diseases
* Pregnancy or lactation
* Allergy to any of the study drugs Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion
* The use of antibiotics or PPI within 2 months before the study
* The presence of dental carious or any untreated cavitated carious lesions and oral abscesses
20 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Jiao Tong University School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hong Lu, MD
Medical Doctor of Division of Gastroenterology and Hepatology of Renji Hospital,Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hong Lu, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Ji Y, Liang X, Lu H. Analysis of by high-throughput sequencing: Helicobacter pylori infection and salivary microbiome. BMC Oral Health. 2020 Mar 20;20(1):84. doi: 10.1186/s12903-020-01070-1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
rjyy20180801
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.